We are live on ! Find out more
BIAF icon

bioAffinity Technologies
BIAF

3 hedge funds and large institutions have $134K invested in bioAffinity Technologies in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more capital inflows, than outflows

Capital inflows: $169K | Capital outflows: $136K

0.21% more ownership

Funds ownership: 0.79% → 1% (+0.21%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

25% less funds holding

Funds holding: 4 → 3 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Financial Engines Advisors
Financial Engines Advisors
California
+$164K
2
UBS Group
UBS Group
Switzerland
+$4.56K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$60K
2
Creative Planning
Creative Planning
Kansas
-$44.4K
3
Jane Street
Jane Street
New York
-$32K

BIAF Hedge Fund Activity: Q4 2022 in Review

3 of the 6,243 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q4 2022, worth a combined $134K — down 30% from $192K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of BIAF and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.

The largest buyer was Financial Engines Advisors, opening a new position worth an estimated $164K. The largest seller was Citadel Advisors, exiting entirely with an estimated $60K sold.

  • 3 institutional investors held bioAffinity Technologies (BIAF) as of Q4 2022, down from 4 in Q3 2022.
  • Funds reported $134K of bioAffinity Technologies stock for Q4 2022, down 30% quarter-over-quarter.
  • 1 fund opened new bioAffinity Technologies positions in Q4 2022 and 2 closed out, a net change of -1 holder.
  • The largest bioAffinity Technologies buyer in Q4 2022 was Financial Engines Advisors, an estimated $164K added.
  • The largest bioAffinity Technologies seller in Q4 2022 was Citadel Advisors, an estimated $60K sold.

Based on aggregated 13F filings for Q4 2022.